A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease
Enrollment status comes from the registry; check the original record for current details.
Read trial record and posted results- Registry ID
- NCT05995353
- Phase
- Phase 3
- Recruitment
- Enrolling participants
- Sponsor
- AbbVie
- Design
- Randomized
- Comparator
- PK Cohort 1: SS1; PK Cohort 1: SS2 Dose A; PK Cohort 1: SS2 Dose B; PK Cohort 1: SS3 Dose A; PK Cohort 1: SS3 Dose B; PK Cohort 2: SS1; PK Cohort 2: SS2 Dose A; PK Cohort 2: SS2 Dose B; PK Cohort 2: SS3 Dose A; PK Cohort 2: SS3 Dose B; Expansion Cohort 3: SS1; Expansion Cohort 3: SS2 Dose A; Expansion Cohort 3: SS2 Dose B; Expansion Cohort 3: SS3 Dose A; Expansion Cohort 3: SS3 Dose B
- Planned enrollment
- 110
- Endpoint
- Cohort 3 (Substudy 2): Percentage of Participants Achieving Pediatric Crohn's Disease Activity Index (PCDAI) Clinical Remission; Cohort 3 (Substudy 2): Percentage of Participants Achieving Endoscopic Response per Simple Endoscopic Score for Crohn's Disease (SES-CD); Cohorts 1 & 2: Maximum Observed Serum Concentration (Cmax) of Risankizumab; Cohorts 1 & 2: Time to Cmax (Tmax) of Risankizumab; Cohorts 1 & 2: Area Under the Serum Concentration-Time Curve Over the Dosing Interval (AUCtau) of Risankizumab
Study ages: 2 Years to 17 Years. Other eligibility criteria apply; see the full criteria above.
Study countries and territories (including sites that may be closed): Belgium, Bulgaria, Canada, China, Czechia, France, Germany, Israel, Italy, Japan, Netherlands, Poland, Puerto Rico, South Korea, Spain, Sweden, Switzerland, Taiwan, Turkey (Türkiye), United Kingdom, United States.
Sites marked recruiting: Belgium, Bulgaria, Canada, China, France, Germany, Israel, Italy, Japan, Netherlands, Poland, Puerto Rico, South Korea, Spain, Sweden, Switzerland, Taiwan, Turkey (Türkiye), United Kingdom, United States. Check the original registry record for locations and study-team contacts; overall recruiting status does not guarantee a local place.
Primary data collection: Apr 2029 (estimated). This is not a results-release date.
No results-posting date in this record.
Evidence 1